These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 23973338)
1. Novel therapeutic strategies for treatment of visceral leishmaniasis. Jain K; Jain NK Drug Discov Today; 2013 Dec; 18(23-24):1272-81. PubMed ID: 23973338 [TBL] [Abstract][Full Text] [Related]
2. [Canine leishmaniasis: evolution of the chemotherapeutic protocols]. Oliva G; Foglia Manzillo V; Pagano A Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724 [TBL] [Abstract][Full Text] [Related]
3. Treatment options for visceral leishmaniasis. den Boer M; Davidson RN Expert Rev Anti Infect Ther; 2006 Apr; 4(2):187-97. PubMed ID: 16597201 [TBL] [Abstract][Full Text] [Related]
4. Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan. Thornton SJ; Wasan KM; Piecuch A; Lynd LL; Wasan EK Drug Dev Ind Pharm; 2010 Nov; 36(11):1312-9. PubMed ID: 20545513 [TBL] [Abstract][Full Text] [Related]
5. Visceral leishmaniasis in children: a review. Palumbo E Minerva Pediatr; 2010 Aug; 62(4):389-95. PubMed ID: 20940672 [TBL] [Abstract][Full Text] [Related]
6. Visceral leishmaniasis: can we dream its eradication? Rege NN J Assoc Physicians India; 2001 Jun; 49():605-8. PubMed ID: 11584933 [No Abstract] [Full Text] [Related]
7. Molecular targets and pathways for the treatment of visceral leishmaniasis. Jain V; Jain K Drug Discov Today; 2018 Jan; 23(1):161-170. PubMed ID: 28919438 [TBL] [Abstract][Full Text] [Related]
8. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India. Murray HW Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475 [No Abstract] [Full Text] [Related]
9. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives. Croft SL; Engel J Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717 [TBL] [Abstract][Full Text] [Related]
14. Drug resistance in visceral leishmaniasis. Maltezou HC J Biomed Biotechnol; 2010; 2010():617521. PubMed ID: 19888437 [TBL] [Abstract][Full Text] [Related]
15. A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis. Chattopadhyay A; Jafurulla M Biochem Biophys Res Commun; 2011 Dec; 416(1-2):7-12. PubMed ID: 22100811 [TBL] [Abstract][Full Text] [Related]
16. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009]. Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391 [TBL] [Abstract][Full Text] [Related]
17. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Meyerhoff A Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069 [TBL] [Abstract][Full Text] [Related]
18. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine. Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038 [TBL] [Abstract][Full Text] [Related]